11:28 AM EST, 01/29/2026 (MT Newswires) -- Eli Lilly ( LLY ) and Repertoire Immune Medicines are launching a collaboration to develop tolerizing therapies for autoimmune diseases.

Repertoire said Thursday it will receive an upfront payment of $85 million and up to an additional $1.84 billion tied to development and commercial milestones, along with royalties on sales.

Repertoire will lead collaboration projects until development candidate nomination, while Lilly will oversee clinical development, manufacturing, regulatory activities and commercialization of any therapies advanced under the partnership.

Price: 1026.66, Change: +2.86, Percent Change: +0.28